Evommune Announces Phase 2b Trial Failure for EVO756 in Atopic Dermatitis
Evommune Inc (NYSE:EVMN) reported that its oral Mas‑related G‑protein coupled receptor X2 antagonist, EVO756, failed to achieve both primary and secondary endpoints in a Phase 2b clinical trial targeting atopic dermatitis (AD). The randomized, double‑blind, placebo‑controlled study enrolled 121 adult participants with moderate‑to‑severe AD and administered the investigational drug over a 12‑week period. The primary efficacy measure—percent change from baseline in the Eczema Area and Severity Index (EASI) score at Week 12—was not met for any dose level, and none of the secondary efficacy endpoints were achieved.
Immediate Commercial Impact
Following the announcement, Evommune’s shares dropped 27% in after‑hours trading on Tuesday, 9 September 2026. The decline reflects investor reaction to the setback in the company’s lead AD program.
Program Adjustments and Future Development
The company stated it will not advance EVO756 for atopic dermatitis but will continue Phase 2b development of the same molecule for migraine prophylaxis. Concurrently, Evommune will shift focus to EVO301, an IL‑18BP fusion protein, which has shown positive Phase 2a proof‑of‑concept data as a potential AD therapy. A Phase 2b trial for EVO301 is scheduled for mid‑2027.
Executive Commentary
Dr. Eugene Bauer, Chief Medical Officer, expressed disappointment, noting the unmet primary endpoint despite the unmet need for new AD treatments. President and Chief Executive Officer Luis Peña emphasized that Evommune maintains a strong balance sheet capable of supporting operations through 2029 and reaffirmed the company’s commitment to advancing its portfolio of chronic inflammatory disease programs.
Safety Profile
EVO756 was reported to be generally well tolerated, with a safety profile consistent with prior studies, despite the efficacy shortfall.